Sanofi India Ltd
NSE:SANOFI

Watchlist Manager
Sanofi India Ltd Logo
Sanofi India Ltd
NSE:SANOFI
Watchlist
Price: 6 286 INR -0.45% Market Closed
Market Cap: 144.8B INR

Sanofi India Ltd
Investor Relations

Sanofi India Ltd., a prominent name in the pharmaceutical landscape, operates as a subsidiary of Sanofi S.A., the global healthcare giant headquartered in France. Its roots in India trace back to the early 1950s when it began importing and distributing vaccines. Over the decades, Sanofi India has evolved into a comprehensive provider of high-quality drugs, contributing significantly to the nation’s healthcare ecosystem. The company focuses primarily on therapeutic segments such as diabetes, cardiovascular diseases, oncology, and vaccines, boasting a robust portfolio of prescription medicines and over-the-counter products. By leveraging a vast network of healthcare professionals and engaging in continuous clinical research and development, Sanofi India ensures its position at the forefront of medical innovation, adhering to a global strategy of patient-oriented solutions and a commitment to improving health outcomes.

Sanofi India's revenue model revolves around its diversified product portfolio, addressing a spectrum of critical health areas. The company generates income through the sale of its flagship products, which include insulin for diabetes management, anti-allergy medications, and innovative therapies for rare diseases, among others. While the domestic market plays a crucial role in its financial framework, Sanofi India also taps into international markets, exporting its high-quality pharmaceutical products across borders. The profitability of the company is further bolstered by its commitment to research and development, enabling it to introduce new drugs and therapies, thus continually expanding its market share. By maintaining strong distribution channels and fostering collaborations with medical institutions and regulatory bodies, Sanofi India ensures its products reach a broad consumer base, perpetuating its growth trajectory in the competitive pharmaceutical scene.

Show more
Loading

Earnings Calls

2025 Q4
May 14, 2025
Show Transcript
Previous
Next
Strong Quarter with Revenue Growth and Market Share Gains
2025 Q4
May 14, 2025

In Q4, Berger Paints India showcased resilience with a 7.4% volume rise and 4.4% revenue increase, achieving market share of 20.3%. Operating profit surged 19.8%, supported by robust gross margins of 41.2%, driven by effective cost management and favorable raw material prices. The decorative segment performed well, with innovative launches catering to rising summer demand. Looking ahead, revenue growth is expected to improve, aiming for double digits, while maintaining operating margins within 15-17%. Bolstered by urban demand and government spending, the overall outlook remains positive despite competitive pressures.

Show Full Analysis

Management

Mr. Rodolfo Hrosz
MD & Director
No Bio Available
Mr. Rachid Ayari
CFO & Whole Time Director
No Bio Available
Ms. Renee Amonkar
Additional Whole Time Director
No Bio Available
Mr. M. K. Narayanaswamy B.Com.,A.I.C.W.A.
Senior Director of Accounting & Taxation
No Bio Available
Ms. Flovie Martins
Head of Corporate Communications & Corporate Social Responsibility
No Bio Available
Ms. Surabhi Kaur
People & Culture Director
No Bio Available
Mr. Sanjay V. Chavan
Head of Country Procurement - India
No Bio Available
Nakul Verma
Senior Director of Public Affairs
No Bio Available
Yasmin Shenoy
Senior Director of Regulatory Affairs
No Bio Available
Mr. N. Suresh Babu
Sales & Customer Engagement Head - Diabetes and Senior Director of Diabetes
No Bio Available

Contacts

Address
MAHARASHTRA
Mumbai
Sanofi House, CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai
Contacts